Health & Environmental Research Online (HERO)


Print Feedback Export to File
7043891 
Journal Article 
Molecular docking, validation, dynamics simulations, and pharmacokinetic prediction of natural compounds against the SARS-CoV-2 main-protease 
Shivanika, C; Kumar, DS; Ragunathan, V; Tiwari, P; Sumitha, A; Devi, BP; , 
2020 
Yes 
Journal of Biomolecular Structure & Dynamics
ISSN: 0739-1102 
TAYLOR & FRANCIS INC 
PHILADELPHIA 
32897178 
WOS:000567586000001 
The study aims to evaluate the potency of two hundred natural antiviral phytocompounds against the active site of the Severe Acquired Respiratory Syndrome - Coronavirus - 2 (SARS-CoV-2) Main-Protease (M-pro) using AutoDock 4.2.6. The three- dimensional crystal structure of the M-pro(PDB Id: 6LU7) was retrieved from the Protein Data Bank (PDB), the active site was predicted using MetaPocket 2.0. Food and Drug Administration (FDA) approved viral protease inhibitors were used as standards for comparison of results. The compounds theaflavin-3-3'-digallate, rutin, hypericin, robustaflavone, and (-)-solenolide A with respective binding energy of -12.41 (Ki = 794.96 pM); -11.33 (Ki = 4.98 nM); -11.17 (Ki = 6.54 nM); -10.92 (Ki = 9.85 nM); and -10.82 kcal/mol (Ki = 11.88 nM) were ranked top as Coronavirus Disease - 2019 (COVID-19) M(pro)inhibitors. The interacting amino acid residues were visualized using Discovery Studio 3.5 to elucidate the 2-dimensional and 3-dimensional interactions. The study was validated by i) re-docking the N3-peptide inhibitor-M(pro)and superimposing them onto co-crystallized complex and ii) docking decoy ligands to M-pro. The ligands that showed low binding energy were further predicted for and pharmacokinetic properties and Lipinski's rule of 5 and the results are tabulated and discussed. Molecular dynamics simulations were performed for 50 ns for those compounds using the Desmond package, Schrodinger to assess the conformational stability and fluctuations of protein-ligand complexes during the simulation. Thus, the natural compounds could act as a lead for the COVID-19 regimen afterin-vitroandin- vivoclinical trials. Communicated by Ramaswamy H. Sarma